Evicenter
MarkdownMedical informationP&T meetings
Cretostimogene grenadenorepvec (CG0070)

BCG-unresponsive high-risk non-muscle-invasive bladder cancer

Manufacturer
CG Oncology
Launch
Not announced
Last updated
161 sources

Economic information and modeling reportBudget impact model

Perspective and time frame

4 evidence topics · 7 sources

Budget impact model of cretostimogene grenadenorepvec: perspective and time frame

No evidence found.